Vertex Pharmaceuticals Inc / Ma (VRTX) Stock Analysis and Metrics

Vertex Pharmaceuticals

NASDAQ: VRTX

$477.36 ▲ +4.27 (+0.90%)

At close: Jul 24, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap121.72 Bn

P/E28.06

P/S9.96

Div. Yield0.00

Revenue Growth (1y) (Qtr)7.82

Add ratio to table…

About

Vertex Pharmaceuticals Inc / Ma is a global biotechnology company that discovers develops and commercializes transformative medicines for serious diseases with a focus on specialty markets. The company has approved treatments for cystic fibrosis sickle cell disease transfusion dependent beta thalassemia and acute pain. It also advances a broad pipeline of investigational programs in immunology kidney disease diabetes and pain. Vertex aims to deliver first in class and best in class therapies that address the underlying biology of disease. The company invests heavily in research and development to identify novel targets and advance candidates through clinical trials. Its strategy emphasizes validation of targets by human biology and use of biomarkers to accelerate development.

Vertex generates revenue primarily from the sale of its approved medicines to specialty pharmacies distributors wholesalers hospitals and clinics. The company’s product portfolio includes cystic fibrosis modulators such as KALYDECO ORKAMBI SYMDEKO TRIKAFTA and ALYFTREK the gene editing therapy CASGEVY for sickle cell disease and transfusion dependent beta thalassemia and the oral pain inhibitor JOURNAVX for acute pain. Manufacturing of small molecule drugs occurs primarily at its internal facilities in Boston while biologics and cell therapies rely on third party partners. Revenue is also supported by collaborations and licensing arrangements that provide milestone payments and royalties. Royalty income from licensed intellectual property also contributes to total revenue.

The company operates through the following segment: pharmaceuticals.

• pharmaceuticals: This segment includes the discovery development manufacturing and commercialization of medicines for cystic fibrosis sickle cell disease transfusion dependent beta thalassemia acute pain and other serious diseases such as immunoglobulin A nephropathy APOL1 mediated kidney disease type 1 diabetes and neuropathic pain. The segment also conducts early discovery research preclinical testing and clinical development across multiple modalities including small molecules proteins and gene edited cells.

Vertex holds a leading position in the cystic fibrosis market where its modulators are used by a large share of patients. The company’s competitive advantages stem from its deep expertise in CFTR modulation its pioneering CRISPR based gene editing therapy and its strong pipeline of novel therapies in kidney disease and pain. In the cystic fibrosis arena Vertex competes with companies developing alternative CFTR modulators and protein correctors. In gene editing for sickle cell disease several biotech firms are pursuing similar CRISPR based approaches. Vertex’s integrated approach from discovery to commercialization and its extensive intellectual property portfolio provide differentiation.

Vertex sells its medicines to a limited number of specialty pharmacy and specialty distributor partners globally as well as to major wholesalers in the United States. Outside the United States the company relies on distributor arrangements and direct sales to hospitals clinics and government supported healthcare providers. The firm has agreements with the three national pharmacy benefit managers and with national and regional payors covering more than 275 million lives. Additionally 21 state Medicaid programs provide coverage for JOURNAVX. Vertex also provides patient support programs that help with insurance navigation and co pay assistance.

Investment Thesis

▲ Bull case

Vertex is building a sustainable diversified revenue engine beyond its cystic fibrosis franchise, with CASGEVY and JOURNAVX collectively contributing over 25% of Q1 FY26 growth, signaling successful expansion into high-unmet-need markets that are less vulnerable to CF-specific patent cliffs. The reimbursement agreement for CASGEVY in Germany adds to a growing list of European and Middle Eastern countries securing sustainable access, which directly addresses a key historical barrier to gene therapy adoption—long-term payer commitment—and positions Vertex to capture a larger share of the ~60,000 eligible SCD/TDT patients globally, particularly as the company ramps cell collection and infusion volumes through its expanding ATC network, with nearly 250 patient referrals and 29 completed infusions already demonstrated in Q2 FY25, indicating a scalable commercialization model that is only beginning to show revenue impact. The FDA acceptance of povetacicept’s BLA for IgAN with a PDUFA date of November 30, 2026, represents a de-risked near-term catalyst that management did not emphasize during the earnings call, despite highlighting the RAINIER trial’s strong interim results, including a 49.8% UPCR reduction versus placebo (p<0.0001) and favorable secondary endpoints in hematuria and Gd-IgA1 reduction; this positions povetacicept as a potential first-in-class therapy in a disease affecting over 1.5 million people globally with no approved disease-modifying treatments, and the planned low-volume auto-injector formulation supports differentiated patient convenience and adherence, which could drive rapid uptake upon approval and lay the foundation for expansion into membranous nephropathy and gMG, where emerging data suggest best-in-class potential. The ongoing advancement of VX-828 as the backbone of the Next-Gen 3.0 CFTR modulator regimen, with healthy volunteer studies nearing completion and plans to initiate CF patient dosing before year-end, offers a meaningful long-term growth lever that is underappreciated by the market; VX-828’s superior in vitro efficacy as the most potent CFTR corrector ever studied by Vertex, combined with its potential to drive patients toward near-normal CFTR function and extend composition-of-matter patent protection to 2039, could reinvigorate the CF franchise beyond ALYFTREK’s current trajectory, especially as the company continues to target younger age groups and rare mutations, ensuring durable demand even as TRIKAFTA faces generic competition later this decade.

Vertex is building a sustainable diversified revenue engine beyond its cystic fibrosis franchise, with CASGEVY and JOURNAVX collectively contributing over 25% of Q1 FY26 growth, signaling successful expansion into high-unmet-need markets that are less vulnerable to CF-specific patent cliffs. The reimbursement agreement for CASGEVY in Germany adds to a growing list of European and Middle Eastern countries securing sustainable access, which directly addresses a key historical barrier to gene therapy adoption—long-term payer commitment—and positions Vertex to capture a larger share of the ~60,000 eligible SCD/TDT patients globally, particularly as the company ramps cell collection and infusion volumes through its expanding ATC network, with nearly 250 patient referrals and 29 completed infusions already demonstrated in Q2 FY25, indicating a scalable commercialization model that is only beginning to show revenue impact. The FDA acceptance of povetacicept’s BLA for IgAN with a PDUFA date of November 30, 2026, represents a de-risked near-term catalyst that management did not emphasize during the earnings call, despite highlighting the RAINIER trial’s strong interim results, including a 49.8% UPCR reduction versus placebo (p<0.0001) and favorable secondary endpoints in hematuria and Gd-IgA1 reduction; this positions povetacicept as a potential first-in-class therapy in a disease affecting over 1.5 million people globally with no approved disease-modifying treatments, and the planned low-volume auto-injector formulation supports differentiated patient convenience and adherence, which could drive rapid uptake upon approval and lay the foundation for expansion into membranous nephropathy and gMG, where emerging data suggest best-in-class potential. The ongoing advancement of VX-828 as the backbone of the Next-Gen 3.0 CFTR modulator regimen, with healthy volunteer studies nearing completion and plans to initiate CF patient dosing before year-end, offers a meaningful long-term growth lever that is underappreciated by the market; VX-828’s superior in vitro efficacy as the most potent CFTR corrector ever studied by Vertex, combined with its potential to drive patients toward near-normal CFTR function and extend composition-of-matter patent protection to 2039, could reinvigorate the CF franchise beyond ALYFTREK’s current trajectory, especially as the company continues to target younger age groups and rare mutations, ensuring durable demand even as TRIKAFTA faces generic competition later this decade.

▼ Bear case

Vertex’s reliance on ALSYFTREK for near-term CF growth masks underlying vulnerabilities in its core franchise, as Trikafta sales missed analyst expectations by $290 million in Q1 FY26 despite being the dominant CF therapy, suggesting potential erosion in market share or pricing pressure that is not being offset by ALYFTREK uptake alone; while ALYFTREK showed a 687% year-over-year sales increase, this growth is off a very small base ($53.9 million in Q1 FY25), and the transition from Trikafta to ALYFTREK remains steady rather than rapid due to patient loyalty and concerns over augmented liver monitoring, implying that the company may be overestimating the speed and completeness of franchise conversion, which could delay the expected revenue uplift from the lower royalty burden and extended patent life of ALYFTREK. The commercialization of CASGEVY faces significant execution risks that are underdiscussed in public communications, including the complex, multi-step manufacturing and patient journey—taking up to 6 months from cell collection to drug product and an additional 4–6 weeks for hospitalization post-infusion—which creates unavoidable revenue lumpiness and limits scalability, as evidenced by only 29 patients completing infusions in Q2 FY25 despite nearly 250 referrals, highlighting bottlenecks in cell collection, manufacturing capacity, or patient scheduling that could persist even with expanding ATCs, and while reimbursement agreements in Germany and other countries are positive, they do not alleviate the operational constraints that may cap annual infusions well below the eligible patient pool of ~60,000, especially in regions with limited transplant infrastructure. Vertex’s pipeline diversification into nephrology and pain carries substantial clinical and regulatory risks that are not being adequately priced in, particularly given the FDA’s rejection of a broad PNP label for suzetrigine, which forces the company to pursue DPN as an initial indication despite the indication’s limited size (~10 million in the U.S.) and competitive landscape, while the success of povetacicept in IgAN, though promising based on interim RAINIER data, remains contingent on full trial results and carries the risk of not translating to meaningful renal function preservation (eGFR slope), which is the ultimate determinant of long-term value in kidney disease therapies, and any failure to demonstrate hard renal outcomes could undermine the premium pricing potential and label expansion hopes for this franchise, leaving Vertex exposed to overinvestment in indications with uncertain clinical differentiation.

Vertex’s reliance on ALSYFTREK for near-term CF growth masks underlying vulnerabilities in its core franchise, as Trikafta sales missed analyst expectations by $290 million in Q1 FY26 despite being the dominant CF therapy, suggesting potential erosion in market share or pricing pressure that is not being offset by ALYFTREK uptake alone; while ALYFTREK showed a 687% year-over-year sales increase, this growth is off a very small base ($53.9 million in Q1 FY25), and the transition from Trikafta to ALYFTREK remains steady rather than rapid due to patient loyalty and concerns over augmented liver monitoring, implying that the company may be overestimating the speed and completeness of franchise conversion, which could delay the expected revenue uplift from the lower royalty burden and extended patent life of ALYFTREK. The commercialization of CASGEVY faces significant execution risks that are underdiscussed in public communications, including the complex, multi-step manufacturing and patient journey—taking up to 6 months from cell collection to drug product and an additional 4–6 weeks for hospitalization post-infusion—which creates unavoidable revenue lumpiness and limits scalability, as evidenced by only 29 patients completing infusions in Q2 FY25 despite nearly 250 referrals, highlighting bottlenecks in cell collection, manufacturing capacity, or patient scheduling that could persist even with expanding ATCs, and while reimbursement agreements in Germany and other countries are positive, they do not alleviate the operational constraints that may cap annual infusions well below the eligible patient pool of ~60,000, especially in regions with limited transplant infrastructure. Vertex’s pipeline diversification into nephrology and pain carries substantial clinical and regulatory risks that are not being adequately priced in, particularly given the FDA’s rejection of a broad PNP label for suzetrigine, which forces the company to pursue DPN as an initial indication despite the indication’s limited size (~10 million in the U.S.) and competitive landscape, while the success of povetacicept in IgAN, though promising based on interim RAINIER data, remains contingent on full trial results and carries the risk of not translating to meaningful renal function preservation (eGFR slope), which is the ultimate determinant of long-term value in kidney disease therapies, and any failure to demonstrate hard renal outcomes could undermine the premium pricing potential and label expansion hopes for this franchise, leaving Vertex exposed to overinvestment in indications with uncertain clinical differentiation.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password